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ABSTRACT
Background: Whereas the negative effect of consuming trans fatty
acids found in partially hydrogenated vegetable oils on cardiovas-
cular disease (CVD) risk is well established, the effect of trans fatty
acids from ruminant sources (rTFAs) on CVD risk factors has not
yet been established, particularly among women.
Objective: We investigated the effects of a butter naturally enriched
in rTFAs, of which vaccenic acid is the predominant isomer, on
plasma lipid concentrations among healthy women.
Design: In a double-blind, randomized, crossover controlled study,
61 healthy women aged 19–70 y were fed 2 isoenergetic diets
lasting 4 wk each. The 2 diets were deﬁned as moderately high in
rTFAs (3.7 g/d, 1.5% of daily energy) and control (0.9 g/d, 0.3% of
daily energy).
Results: No signiﬁcant effect of the rTFA diet was found on total
plasma cholesterol, LDL cholesterol, apolipoprotein B, apolipopro-
tein A-I, and triglyceride concentrations compared with the control
diet. There was a small yet statistically signiﬁcant reduction in
plasma HDL-cholesterol concentrations with the rTFA diet
(22.8%; P = 0.004), which was signiﬁcant (P for the BMI · treat-
ment interaction = 0.006) among women with a BMI (in kg/m
2)
25 (25.2%; P = 0.004; n = 18) but not among women with a BMI
,25 (21.2%; P = 0.13; n = 43).
Conclusions: These results suggest that an increase in dietary
rTFAs equivalent to ;1% of daily energy has no signiﬁcant effect
on LDL but may be associated with a reduction in plasma HDL-
cholesterol concentrations, particularly in overweight women. This
trial is registered at clinicaltrials.gov as NCT00930137. Am J
Clin Nutr 2012;95:318–25.
INTRODUCTION
Whereas the negative effect of consuming TFAs
4 found in
PHVO on health, particularly on CVD risk, is well established
and recognized (1), the association between dietary rTFAs and
CVD risk has yet to be more formally established. A recent
quantitative review has suggested that TFAs from PHVOs and
rTFAs may have similar effects on plasma lipids (2), but this
conclusion remains uncertain because it is based on only 5
studies (3–7). Data in particular subgroups of the population are
also utterly lacking. Speciﬁcally, women are greatly un-
derrepresented in the 5 rTFA clinical studies on blood lipids
published to date, representing only 11% of subjects. In-
terestingly, in the one study that did include both sexes, the
increase in the LDL-/HDL-cholesterol ratio in women after
consumption of rTFAs (5% of energy) was 2.4 times the change
seen in men (4). In contrast, results from epidemiologic studies
suggest that women may respond more favorably to dietary
rTFA exposure than men (8, 9). These differences emphasize the
need for further research documenting the effect of rTFAs in
various subgroups of the population, particularly among women.
In a previous controlled feeding study in men, we showed that
a moderately elevated intake of rTFAs (1.5% of daily energy) had
no effect on CVD risk factors, which suggests that, even at the
upper limit of human consumption, rTFAs may have little effect
on CVD risk factors (3). This is consistent with previous epi-
demiologic studies in men, which have generally reported no
effect of rTFAs on CVD risk across usual dietary intakes (8, 10,
11). The extent to which a moderate increase in dietary intake of
rTFAs has an effect (positive or negative) on plasma lipid con-
centrations in women has not been studied yet. Hence, this study
was designed to investigate the effect of a high but yet achievable
intake of rTFAs on plasma lipid concentrations among healthy
women of various ages and with a broad range of plasma LDL-
cholesterol concentrations.
SUBJECTS AND METHODS
Population
Seventy-two women were recruited in the Que ´bec City met-
ropolitan area through the media and electronic newsletter to
participate in the study. Recruitment took place at the Institute of
Nutraceuticals and Functional Foods between September 2009
and April 2010. Subjects were initially screened on the basis of
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subjects recruited for the study had to be 18–70 y of age, to have
a BMI (in kg/m
2) between 18 and 30, and to have a plasma LDL-
cholesterol concentration within 2.0–4.2 mmol/L. Exclusion
criteria were the presence of a previous history of CVD, type 2
diabetes, monogenic dyslipidemia, or any diagnosed endocrine
disorders; the use of medications for hyperlipidemia or hyper-
tension; and a signiﬁcant weight change within the 6 mo before
the experiment. Among premenopausal women, only those with
a regular menstrual cycle (25–35 d) for the past 3 mo were in-
cluded. This combined with the fact that measurements were
performed at the end of each 4-wk diet maximized the chance of
having women being tested within the same phase of their
menstrual cycle. All postmenopausal women were eligible, ir-
respective of their hormone supplementation status. Women
with nutritional habits such as vegetarianism, with food allergies
or aversion to foods included in the experimental diets, with
alcohol consumption of .2 drinks/d, and elite athletes were
excluded. Smokers and women who use contraceptive agents
were not excluded from the study. FSH measurements were
performed to conﬁrm the premenopausal or postmenopausal sta-
tus (FSH ,20 IU/L or FSH .25 IU/L). The study protocol was
fully explained to all participants, who gave written informed
consent at the beginning of the study. The protocol was approved
by the Clinical Research Ethics Committee of Laval University.
Production of the TFA-enriched milk fat
The butter enriched with rTFAs was obtained by altering the
cows’ diets as previously described (3), with slight modiﬁcation.
Brieﬂy, a group of 31 cows were fed a mixed diet composed of
concentrates + alfalfa and corn silages with the addition of 3.6%
corn oil. Milk samples were taken after 4 wk, and the 13 cows
with the highest concentration of trans-18:1 continued con-
suming the diet for the purpose of milk collection and the
manufacturing of the rTFA-enriched butter. The control low-
rTFA butter was obtained from the Canadian Dairy Commission
(March–April 2009 production). The characterization of the
fatty acid composition of experimental butterfat was carried out
by gas chromatography (HP 5890; Hewlett-Packard Co) with
a 100-m CP Sil 88 capillary column (Chrompack; Middelburg)
and a ﬂame ionization detector (12). Feeding corn oil to dairy
cows increased the total TFA content of milk fat without sig-
niﬁcantly modifying its isomeric distribution. The absolute
amount of vaccenic acid (18:1t-11), the predominant TFA in the
TFA-enriched butter, was 3.7 times that in the control butter and
accounted for 37.1% and 47.5% of total rTFAs in the control
butter and the rTFA-enriched butter, respectively (Table 1). The
16:1t isomers were not measured.
Diets and study design
The current study was undertaken as a double-blind, ran-
domized, crossover controlled study in which each participant
was assigned to 2 sequences of 2 different isocaloric diets lasting
4 wk each. Randomized treatment sequences were computer-
generated by one of the investigators (BL) and then passed on to
the research team without any knowledge of participant’s status
and eligibility. Each diet was separated by a 3-d period (week-
end). The 2 experimental diets used in the current study were the
rTFA diet (3.7 g/d) and the control diet low in rTFAs (0.9 g/d,
control diet), with a difference between the 2 diets of 2.8 g rTFA.
SourcesofrTFAs,suchasruminantmeat(lamb,veal,orbeef)and
nonskim dairy products, were not used in the formulation of the
diets so that differences in the rTFA content between diets came
exclusively from the experimental butters. Inclusion of any other
foods with a high SFA content was also minimized to achieve the
prescribed 10% SFA content. Speciﬁc vegetable and animal oils
and fat were incorporated into each diet to attenuate differences
in the amounts of SFAs and unsaturated fatty acids between
treatments (see Supplemental Table 1 under “Supplemental
data” in the online issue). As a result, the 2 experimental fats
used to formulate the predetermined diets contained relatively
comparable amounts of every major type of SFA and PUFA,
whereas rTFAs were mainly substituted by 18:1c fatty acids.
Both diets were identical in terms of menus, calories, and
macronutrient composition, with the exception of rTFAs and
18:1c (Table 2). On average, the 2 experimental diets were
formulated to provide 54% of daily energy from carbohydrate,
15% from protein, and 33% from fat. The rTFA diet provided
1.5% (exact value: 1.474%) of daily energy intake as rTFAs, and
the control diet provided 0.3% (exact value: 0.342%) of daily
energy intake as rTFAs. Because some of the foods used in the
diets did contain traces of TFAs from PHVO, there was
TABLE 1
Fatty acid composition of the experimental butter enriched with rTFAs and
of the control butter
1
Control butter
rTFA
butter
SFAs 68.4 54.2
4:0 4.7 3.7
6:0 2.3 1.5
8:0 1.3 0.8
10:0 2.9 1.6
12:0 3.3 1.9
14:0 11.0 7.9
15:0 1.3 0.8
16:0 28.4 20.8
17:0 2.1 1.5
18:0 10.8 13.5
20:0 0.2 0.2
22:0 0.1 0.1
MUFAs 23.0 27.2
14:1c 1.1 0.8
16:1c 1.4 1.1
18:1c (total) 20.5 25.0
20:1c 0.2 0.2
PUFAs 3.1 3.0
18:2c 2.1 2.1
18:3c 0.5 0.4
Others
2 0.6 0.5
TFAs 4.6 13.2
18:1t (total) 4.1 12.4
18:1t-11 (vaccenic acid) 1.7 6.3
18:2t (total)
3 0.5 0.8
18:2c-9t-11 (CLA) 0.8 2.4
1 Values are percentage of butter fat. 16:1t isomers were not measured
in either of the experimental butters. CLA, conjugated linoleic acid; rTFA,
trans fatty acid from ruminant sources; TFAs, trans fatty acids.
2 18:4c, 20:2c, 20:3c, 20:4c, 22:2c, 20:5c, 22:4c, and 22:5c.
3 18:2t-9t-12, 18:2c-9t-12, 18:2t-9c-12, and 18:2t-11c-15.
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the 2 diets. These TFAs from PHVO speciﬁcally were obtained
by calculation and not chemical analysis based on the food
database and food analysis software used for the study (Nutri-
tion Data System, version 4.03_31; Nutrition Coordinating
Center). Estimates of usual energy intake were ascertained at
baseline by using a validated food-frequency questionnaire (13).
Each participant was assigned to a value of energy intake that
was revised when required to minimize body weight ﬂuctuation
during the study. Body weight was recorded on all weekdays just
before lunch. All meals were provided to participants so that
control for energy and macronutrient intakes was optimized. On
weekdays, subjects came to the Clinical Investigation Unit at the
Institute of Nutraceuticals and Functional Foods at Laval Uni-
versity to consume their lunch under the supervision of at least
one member of the research team, who was blinded to subject’s
treatment. At that time, they were also provided with their
dinner and the next day’s packaged breakfast to take home.
Weekend meals were prepared, packaged, and provided at the
Clinical Investigation Unit on the Friday lunchtime visits. The
breakfast meal represented 26% of the daily energy intake,
whereas the lunch and dinner meals each provided 37% of daily
energy intake. Subjects were instructed to consume their entire
meals. Subjects had free access to water and to caffeine-free diet
beverages. Consumption of tea and coffee was allowed within
a limit of 2 cups/d (500 mL/d). Supplementation with vitamins
and natural health products, as well as alcohol consumption,
was strictly forbidden during all treatment phases. Throughout
the study, participants were asked to maintain their usual level of
physical activity, which was evaluated by a weekly question-
naire completed by the subjects. The subjects were asked to
remain sedentary on the 3 d preceding blood sampling at the
various stages of the study.
Compliance
A 7-d cyclic menu was developed to reﬂect a typical Canadian
diet to optimize compliance with the protocol. A checklist was
provided to all participants to identify foods that they had or had
not consumed when eating outside the Clinical Investigation
Unit. This list also provided space to indicate unlisted but per-
mitted food items that had been consumed in addition to the
formulated diets. Concurrent use of medication during the ex-
perimental protocol was also tracked with the use of this list.
However, participants had to notify the physician in charge of the
clinical aspects of the study before initiating any medication.
Risk factor assessment
Plasma lipid concentrations
Fasting blood samples (12-h fast) were collected from an
antecubital vein at the beginning (day 1) and at the end (days 25
and 26) of each experimental period in 77% of the participants.
The mean of the 2 postdiet values were used for all variables in
these subjects. In the remaining 33% of subjects, blood samples
were taken only once on the last day (day 26) of each diet.
Assessment of the plasma lipid proﬁle was performed according
to methods described previously (14–17). The CV for plasma
lipid concentrations measured on samples taken on 2 consecutive
days averaged 2.7% for total cholesterol, 3.6% for LDL cho-
lesterol, 3.0% for HDL cholesterol, and 9.8% for triglycerides.
CETP mass, apo A-I, and apo-B concentrations
Serum apo A-I and apo B were measured with ELISA Imu-
noassay kits (Alerchek Inc). The plasma CETP mass concentration
TABLE 2
Mean nutritional composition of the 2 experimental diets
1
Control
diet
rTFA
diet
Energy (kcal/d)
2 2279 6 268 2280 6 233
Carbohydrates (% of energy) 54.4 54.3
Proteins (% of energy) 15.0 15.0
Lipids (% of energy) 33.0 33.0
SFAs 9.9 10.3
4:0 0.4 0.4
6:0 0.2 0.2
8:0 0.1 0.1
10:0 0.2 0.2
12:0 0.3 0.2
14:0 0.9 1.0
16:0 5.4 5.0
17:0 0.2 0.2
18:0 2.1 2.7
20:0 0.1 0.1
22:0 0.2 0.2
MUFAs 14.2 12.8
14:1c 0.1 0.1
16:1c 0.4 0.4
18:1c (total) 13.6 12.1
20:1c 0.2 0.2
PUFAs 5.9 5.8
18:2c 5.2 5.1
18:3c 0.6 0.6
Others 0.1 0.0
TFAs from butters
3 0.3 1.5
18:1t (total) 0.3 1.4
18:1t-11 (VA) 0.1 0.7
18:2t (total) 0.0 0.1
TFAs from PHVO
4 0.3 0.3
16:1t (total) 0.0 0.0
18:1t (total) 0.2 0.2
18:2t (total) 0.0 0.0
Total ﬁbers (g/d) 25.7 25.7
Cholesterol (mg/d) 292 294
1 Numbers are based on the nutritional composition of the formulated
diets estimated by using the food and nutrient database. Only the individual
fatty acids presented in Table 1 are reproduced here, with the exception of
the TFAs from PHVO, which have been added to the table. This explains
why the sum of the individual fatty acids do not add up to the exact total
percentage of the main fats in the diets. The rounding of the numbers to the
ﬁrst decimal point may also have the effect that the sum of the individual
fatty acids in one category does not add up to the exact total of that category.
PHVO, partially hydrogenated vegetable oil; rTFA, trans fatty acid from
ruminant sources; TFAs, trans fatty acids; VA, vaccenic acid.
2 Values are means 6 SDs.
3 The composition of the experimental butters was incorporated into
our food database to derive the percentage of energy from the experimental
butters as part of the whole diet.
4 0.7 g TFAs from foods containing PHVO are shown separately from
rTFAs. The same foods in the same amounts contributed to the intake of
TFAs from PHVO (0.3% of energy) in both diets.
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noassay kit (Wako Chemicals Inc).
Hepatic and endothelial lipases
Serum HL and EL concentrations were measured using
commercial ELISA kits according to the manufacturer’s protocol
(USCN Life Science Inc).
Anthropometric measures and blood pressure
At the beginning and at the end of each experimental diet, body
weightandwaistandhipcircumferencesweremeasuredaccording
to standardized procedures (18). Systolic and diastolic blood
pressureswereaveragedfrom3measurementstakenaftera10-min
rest in the sitting position with an automated blood pressure
monitor (BPM 300-BpTRU model; Vital Signs Monitor).
Statistical analyses
The main hypothesistestedin thisstudy wasthatanincreasein
;1% of energy as rTFA has no signiﬁcant effect on plasma
LDL-cholesterol concentrations with a 2-tailed a = 0.05 and b =
0.2. The pooled SD of the change in plasma LDL-cholesterol
concentrations in our previous study of rTFAs in men (similar
design and similar diets) was 0.39 mmol/L (3), and we assumed
similar numbers in women. On the basis of these numbers and
on a baseline LDL-cholesterol concentration estimated a priori
at 3.0 mmol/L, 55 participants completing the study were re-
quired to be able to detect a 5% change in LDL cholesterol
with the rTFA compared with the control diet. Secondary out-
comes were changes in HDL cholesterol and in the total/HDL
cholesterol ratio. On the basis of the pooled SD for the change in
HDL cholesterol in our previous study in men (3), 55 partic-
ipants were sufﬁcient to detect a signiﬁcant increase or decrease
in HDL cholesterol that would be as small as 0.055 mmol/L (ie,
3.9%, 2-tailed a = 0.05 and b = 0.2). A 65% change in the total/
HDL cholesterol ratio was calculated to be signiﬁcant (2-tailed
P , 0.05) with a power of 1.0. The study design allowed us to
detect a 5-mm Hg difference in systolic and a 3.6-mm Hg dif-
ference in diastolic blood pressure between treatments (80%
power at P = 0.05). Finally, we were able to detect with a power
of 80% a correlation of r . 0.37 within a sample of n =5 5
subjects (P  0.05). On the basis of an anticipated 15% dropout
rate, we had initially planned to recruit 64 women. However,
recruitment was very successful, so that 72 women were ﬁnally
randomly assigned to treatment sequences.
Data are reported as means 6 SDs and the percentage of
changes from the control diet in the tables, unless stated oth-
erwise. The main analysis compared values of each outcome
measured at the end of the 2 isocaloric diets, ie, values after the
rTFA diet compared with values after the control diet. Data were
analyzed by using the PROC MIXED procedure for repeated
measures in SAS (v9.2; SAS Institute Inc). Menopausal status,
weight, treatment sequence, and baseline values were included
as covariates in all models. Their interaction with the main
treatment effect was also tested, but none were signiﬁcant; there-
fore, they were removed from ﬁnal models. Variables with a skewed
distribution were log-10 transformed before statistical analysis.
Differences at P  0.05 (2-sided) were considered signiﬁcant.
RESULTS
Characteristics of subjects at baseline and compliance
Of the 72 women enrolled in the study, a total of 8 dropped out
because they felt the study protocol was too demanding. Of the
remaining 64 subjects who completed the intervention, 2 were
excluded because their menopausal status changed during the
course of the study (assessed on the basis of FSH values) and 1
was excluded because of missing data for several outcomes
(Figure 1). The clinical data of the 72 women recruited in the
study were very similar to the data in the 61 completers included
in the ﬁnal analyses (data not shown). The risk proﬁle of com-
pleters at screening is shown in Table 3. Women had a mean
(6SD) age of 38.3 6 17.1 y and were generally in good health,
with average blood lipid concentrations within normal values.
Among premenopausal women, 55.2% (n = 21/38) were using
oral contraceptives, whereas 37.7% (n = 23) of the participants
were postmenopausal. Few of the women were taking concur-
rent medication (thyroid, n = 4; antidepressant/antipsychotic,
n = 4; nonsteroidal anti-inﬂammatory, n = 3; proton pump in-
hibitors, n = 2). Approximately 95% of the weekly food
checklists were returned, from which we calculated that 98.9%
of the food provided had been consumed.
Anthropometric measures
No signiﬁcant difference in waist circumference was found
afterthe2diets.Asmallyetsigniﬁcantdifferenceinbodyweight
was found between the 2 diets (Table 3), which was therefore
accounted for in all subsequent analyses. Exclusion of the
variations in body weight as a covariable in the statistical model
had no effect on the results (data not shown). No difference in
reported physical activity, expressed as total metabolic equiv-
alent tasks, was found between the diets (P = 0.97; data not
shown).
Cardiovascular disease risk factors
No signiﬁcant changes in total plasma cholesterol, LDL
cholesterol, apo B, or triglyceride concentrations were found
after the rTFA diet compared with the control diet (Table 3).
Plasma HDL-cholesterol concentrations were signiﬁcantly lower
after the rTFA diet than after the control diet (22.8%; P = 0.004),
whereas no signiﬁcant change in plasma apo A-I concentrations
was found after the rTFA diet. A signiﬁcant BMI · diet interaction
on HDL-cholesterol concentrations was found (P-interaction =
0.006). Speciﬁcally, women with a BMI 25 (n = 18) had a sig-
niﬁcant 5.2% reduction in plasma HDL-cholesterol concentrations
after the rTFA diet compared with the control diet (95% CI:
28.5%, 21.7%; change estimate: 20.09 mmol/L; P = 0.004),
whereas no change in HDL cholesterol was found among women
with a BMI ,25 (21.2%; 95% CI: 23.4, 1.0%; change estimate:
20.03 mmol/L; P = 0.13). No such BMI · diet interaction was
seen with LDL cholesterol or apo B. Menopausal status and age
showed no signiﬁcant interaction with diet on HDL-cholesterol or
LDL-cholesterol concentrations. Finally, the rTFA diet tended to
increase the total/HDL cholesterol and LDL/HDL cholesterol ra-
tios, but not signiﬁcantly so.
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Comparisons between the rTFA and control diets showed no
signiﬁcant differences in mean (6SEM) plasma concentrations
of CETP (3.4 6 0.1 and 3.5 6 0.1 lg/mL, respectively; P = 0.3),
HL (112 6 13 and 110 6 12 U/L, respectively; P = 0.6), and EL
(333 6 107 and 310 6 96 ng/mL, respectively; P = 0.8). There
was also no signiﬁcant correlation between diet-induced changes
in plasma HDL cholesterol or apo A-I concentrations and con-
current variations in plasma EL, HL, and CETP concentrations
(data not shown).
DISCUSSION
The study investigated how an increase of 1.2% of energy as
rTFAs (difference between the rTFA diet and the control diet: 2.8
g rTFA/d) affects plasma lipid concentrations in healthy women.
In Canada, the average total TFA intake from any source has de-
clined from 8.4 g/d (3.7% of energy) in the mid-1990s to 4.8 g/d
(2.0% of energy) in 2004 and to 3.4 g/d (1.4% of energy) in 2008
(19). A report from 2006 has estimated the speciﬁc intake of TFA
from ruminant sources in Canada to be ;1 g/d (20), and this value
is very unlikely to have changed since then. Thus, our study in-
vestigated the effect of a 3-fold increase in dietary rTFAs compared
with current estimates of intake in Canada. It can therefore be
considered to be relatively high, but theoretically achievable and of
nutritional relevance.
A large epidemiologic study among women has shown that,
unlike TFAs from PHVO, an increased intake of rTFAs tended to
be associated with a lower risk of CVD in women (9). Other data
from epidemiologic studies have reported no signiﬁcant effect of
rTFA intake on CVD risk in various populations (8, 10, 21). Data
from clinical trials do not entirely support these observations. On
the basis of a comprehensive analysis of published clinical trials,
Brouweretal(2)havesuggestedthatrTFAsandTFAsfromPHVO
may have similar elevating effects on the LDL/HDL cholesterol
ratio. We stress that this compounded analyses of the effects of
TFAs from PHVO on plasma lipids is based on 23 studies to date,
whereas rTFAs have been investigated in only 5 studies so far (2),
excluding the current study. We also stress that only 21 women
have been included so far in previous clinical studies of rTFAs,
representing only 11% of all participants. This is a key point
because it has been suggested that men and women may respond
differently to nutritional changes. In particular, Chardigny et al (4)
have shownthatthe increaseintheLDL/HDLcholesterol ratiowith
anincreasedrTFAintake(5%ofenergy)wasinfact2.4-foldgreater
in women than was the change seen in men. This emphasizes the
importance of having additional adequately powered and optimally
controlled studies to draw ﬁrm conclusion on the effects of rTFAs
on blood lipids, particularly among women.
We showed that substituting 1.2% of energy as rTFAs in place
of cis-MUFAs had no effect on LDL cholesterol (estimated
change: 0.01 mmol/L; NS) but reduced plasma HDL-cholesterol
concentrations in healthy women (estimated change: 0.05 mmol/
L; signiﬁcant). These effects are not entirely consistent with data
from the quantitative review by Brouwer et al (2), which would
have predicted an increase of 0.045 mmol/L for LDL cholesterol
and a reduction of only 0.009 mmol/L for HDL cholesterol.
These discrepancies can be explained by several factors. First,
sex may be a factor and women are greatly underrepresented in
FIGURE 1. Flow of patients throughout the study. rTFA, trans fatty acid from ruminant sources.
322 LACROIX ET ALthe literature on rTFA, because most studies have been con-
ducted in men exclusively, as indicated above. The status of
participants at baseline may have also inﬂuenced the outcome.
In the current study, participants were healthy and nonobese as
a group. Although age, risk factor proﬁle at baseline, and
menopausal status did not modulate the effects of rTFAs on
blood lipids, a signiﬁcant BMI · diet interaction was found for
HDL cholesterol, with the reduction in plasma HDL cholesterol
being signiﬁcantly more pronounced among overweight women
than among normal-weight women. This ﬁnding is consistent
with the concept that adiposity may signiﬁcantly modulate the
effect of nutritional changes on plasma lipid and nonlipid risk
factors (22). Consumption of rTFAs led to a small yet signiﬁcant
reduction in body weight. Because there was no concurrent
change in waist circumference, we believe that this small change
in body weight was most likely coincidental and of little im-
portance in this study.
Previous studies have suggested that the reduction in plasma
HDL-cholesterol concentrations with TFA intake (mainly from
PHVO) compared with cis-MUFAs may be imputed to increased
CETP activities. Exploratory analyses suggested that the HDL-
lowering effect seen with rTFAs in the current study was apparently
not mediated by changes in plasma CETP, HL, and EL concen-
trations, which is consistent with data from Aro et al (23), who
reported no signiﬁcant effect of TFA on CETP activity compared
with diets high in SFAs, despite a signiﬁcant change in HDL-
cholesterol concentrations between diets (23). Whether information
on enzyme activities rather than plasma concentrations would have
yielded similar results is uncertain. Kinetic studies have shown
that the reduction in plasma HDL-cholesterol concentrations
with dietary TFAs from PHVO was largely attributable to an
enhanced clearance of apo A-I, rather than to a reduced pro-
duction rate (24). We hypothesize that similar mechanisms may
be at play with regard to rTFA. The large variation in the re-
sponse of apo A-I to treatments may have blunted a signiﬁcant
effect in our study.
The total/HDL cholesterol ratio was nontrivially increased by
;10% after both dietary regimens (control and rTFA diets)
compared with values at screening. We analyzed the usual food
intake of the participants before undertaking the study in an
attempt to identify factors underlying these changes. Their es-
timated usual intake in saturated fat was 10.1%, whereas their
intake in ﬁbers averaged 27.4 g/d. These values are not different
from the values achieved during both the control and the rTFA
diets (10% of energy for SAT and 25.7 g/d for ﬁbers). Alcohol
intake on the other hand was different (screening: 5.1 g/d; study:
0.1 g/d), which may explain at least the slight reduction in
plasma HDL cholesterol between screening and the diets and
hence in the total/HDL cholesterol ratio as well.
In a recently published double-blind, randomized trial con-
ductedinhealthymenandwomen,alimitedincreaseintherTFA/
SFA ratio (4%/63% compared with 2.8%/72%) in dairy products
was associated with improvements in LDL cholesterol and the
LDL/HDL cholesterol ratio but not in HDL-cholesterol con-
centrations(25).Afurther increasein therTFA/SFAratioshowed
no additional beneﬁt and had similar effects in both sexes. This
study was obviously very different from ours, because several
changes in many fatty acids were being compared, other than just
those between TFAs and cis-MUFAs. Tricon et al (7) have shown
in men that consumption of a CLA-rich diet in which the rTFA
content was close to that attained in our study (4.7 g/d, pre-
dominantly vaccenic acid) had no effect on plasma triglycerides,
total cholesterol, and LDL cholesterol, but led to a signiﬁcant
increase in the LDL/HDL cholesterol ratio compared with the
control diet. A trend toward an increase in the total/HDL cho-
lesterol ratio was also observed with the CLA-rich diet. These
effects could not be ascribed to rTFAs or CLAs because both
were given concurrently in that study.
TABLE 3
Body-composition variables and plasma lipid concentrations at screening and at the end of the dietary intervention in the 61 subjects
1
After the diet
Screening Control rTFAs Estimated change 95% CI Change from control P
2
%
Weight (kg) 63.5 6 8.8
3 62.8 6 8.4 62.5 6 8.3 20.3 20.5, 20.1 20.4 0.013
BMI (kg/m
2) 23.6 6 2.9 23.3 6 2.8 23.2 6 2.8 20.1 20.2, 20.0 20.4 0.013
Waist girth (cm) 81.1 6 8.8 78.7 6 8.1 78.6 6 8.3 20.1 21.1, 0.9 20.1 0.868
Systolic BP (mm Hg) 104.1 6 9.4 102.2 6 10.5 103.3 6 9.5 1.1 21.1, 3.3 1.1 0.306
Diastolic BP (mm Hg) 68.7 6 6.3 66.9 6 6.6 67.6 6 7.4 0.7 21.0, 2.4 1.0 0.436
Cholesterol (mmol/L) 5.11 6 0.97 5.24 6 0.98 5.21 6 0.98 20.04 20.12, 0.04 20.8 0.324
LDL-C (mmol/L) 2.84 6 0.77 3.12 6 0.82 3.12 6 0.84 0.01 20.06, 0.08 0.3 0.771
apo B (g/L)
4 0.96 6 0.33 1.00 6 0.41 1.01 6 0.42 0.01 20.12, 0.14 1.2 0.831
HDL-C (mmol/L) 1.78 6 0.42 1.69 6 0.37 1.64 6 0.37 20.05 20.08, 20.01 22.8 0.004
apo A-I (g/L)
4 1.52 6 0.73 1.63 6 0.99 1.46 6 0.56 20.18 20.41, 0.05 211.0 0.089
Triglycerides (mmol/L)
4 1.04 6 0.44 0.96 6 0.46 0.96 6 0.49 0.00 20.06, 0.06 20.5 0.997
Total/HDL-C
4 2.95 6 0.66 3.21 6 0.81 3.28 6 0.83 0.07 20.01, 0.14 2.1 0.053
LDL/HDL-C
4 1.67 6 0.56 1.92 6 0.68 1.99 6 0.70 0.06 20.00, 0.13 3.2 0.060
apo B/apo A-I
4 0.72 6 0.33 0.71 6 0.36 0.78 6 0.39 0.07 20.05, 0.18 9.5 0.144
1 apo, apolipoprotein; BP, blood pressure; C, cholesterol; rTFAs, trans fatty acids from ruminant sources.
2 Diets were compared by using mixed models for repeated measures, with adjustment for baseline values (screening), menopausal status, sequence, and
weight (on diet). Postdiet values for body weight were not included in the analysis of weight and waist circumference.
3 Mean 6 SD (all such values).
4 Analysis was performed on log-transformed values.
RUMINANT TRANS FAT AND CVD RISK 323The current study had strengths as well as limitations. Unlike
in previous studies of rTFAs speciﬁcally, the large sample size,
thecontrolledfeedingnatureofthestudydesign,andtherepeated
measurements at the end of each diet made it powerful to detect
very small changes in risk factors. This was also one of the ﬁrst
studies to have investigated the effect of a butter enriched in
rTFAs in women speciﬁcally. Although the sample size allowed
us to detect a 5% change in LDL cholesterol, it is possible that
smaller increases may still affect long-term CVD risk. Unlike in
many previous studies of rTFAs, the dietary intake of rTFAs in
this study, although still high, was theoretically achievable and
therefore of clinical relevance. Although vaccenic acid is the
predominant trans isomer of rTFAs, it represented ,50% of all
rTFAs in the rTFA-enriched butter. Because other rTFA isomers
were increased in the rTFA-enriched butter (eg, 18:2t increased
by 56% compared with the control butter), it was therefore not
possible to ascribe the change (or lack thereof) in plasma lipids
in our study to vaccenic acid alone. Plasma concentrations of
trans-palmitoleate (16:1t-7), also found in dairy fat, was found
to be associated with lower insulin resistance, the presence of
atherogenic dyslipidemia, and incident diabetes in the large
Cardiovascular Health Study cohort (26). The speciﬁc 16:1t-7
and other 16:1t isomer contents of the experimental butters in
the current study were not measured and their effect on the study
outcomes cannot be commented on. These usually represent
,1% of all fatty acids in dairy fat (27, 28). Finally, the study
was conducted over a short-term period, and longer-term effects
—particularly on other nonlipid CVD risk factors—cannot be
ruled out and need further investigation.
In summary, we showed in healthy women that an increase in
thedietaryintakeofrTFAscorrespondingto1.2%ofdailyenergy
had no signiﬁcant effect on plasma LDL-cholesterol concen-
trations but had a small HDL-lowering effect, particularly in
overweight women. The long-term effect of these changes on
CVD risk is unknown. Whether these observations extend to
patients with cardiometabolic abnormalities, such as the meta-
bolic syndromeand diabetes,will also needto be addressed in the
future.
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